Monday October 21, 2013 0 commentsFORT COLLINS - KromaTiD Inc. today announced the launch of its directional Genomic Hybridization (dGH) line of mutation discovery and detection assays.
The new products provide researchers with unique tools for discovering new disease-causing mutations as well as studying the genetic roots of diseases such as cancers and developmental disorders, the company said.
Based on a proprietary chromatid-specific imaging platform, dGH products are the only imaging assays capable of determining DNA sequence, location and orientation data in a single test, KromaTiD said.
"Mutations such as deletions and chromosomal rearrangements (such as inversions) have not been fully appreciated until recently," said Dr. Joel Bedford, chair of the KromaTiD Scientific Advisory Board.
"Mutations such as deletions and chromosomal rearrangements cause genetic disease, including cancers and autism, by disrupting vital biological processes. Up until the launch of KromaTiD's dGH products, however, most inversions - especially small ones - have been invisible to researchers.
"Now, with the availability of dGH to complement highly sophisticated sequencing approaches, we can begin to understand the full scope and impact of these DNA rearrangements on human disease."
Christopher Tompkins, KromaTiD president and COO, said the company is committed to making the assays widely available and affordable.
"We have been test-marketing our dGH kits for several months, and have been delighted with the response from the research community," he said. "With the launch of the dGH product line, KromaTiD is adding an essential tool to the disease research toolbox."